Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Gains from Investment Securities: 2023-2024

Historic Gains from Investment Securities for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $3.7 million.

  • Inhibrx Biosciences' Gains from Investment Securities rose 157.58% to $19,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $116,000, marking a year-over-year decrease of 97.76%. This contributed to the annual value of $3.7 million for FY2024, which is 124.42% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Gains from Investment Securities stood at $3.7 million for FY2024, which was up 124.42% from $1.6 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Gains from Investment Securities registered a high of $3.7 million during FY2024, and its lowest value of $1.6 million during FY2023.
  • Moreover, its 2-year median value for Gains from Investment Securities was $2.7 million (2023), whereas its average is $2.7 million.
  • Data for Inhibrx Biosciences' Gains from Investment Securities shows a peak YoY skyrocketed of 124.42% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Gains from Investment Securities (Yearly) stood at $1.6 million in 2023, then soared by 124.42% to $3.7 million in 2024.